Independent
Tenure on this board
2.5 yrs
Meeting calendar
INBX · Annual meeting · Wednesday, June 3, 2026
Inhibrx Biosciences Inc
2 nominees · 2 ballot items.
Election of two Class II directors; Ratification of appointment of BDO USA, P.C. as independent auditors for 2026.
Market cap
$1.3B
1Y TSR
+340.3%
Board grade
B
Record date
Apr 7, 2026
Filing
DEF 14A
Meeting concluded · Jun 3, 2026
Follow how the vote landed and what changed on Inhibrx Biosciences Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class II Directors
ManagementBoard: FORElect two Class II directors (Douglas G. Forsyth and Kimberly Manhard) to serve until the 2029 Annual Meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the Audit Committee’s selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
2.5 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 9.8% | 1,442,707 | $97M |
| 2 | VIKING GLOBAL INVESTORS LP | 9.8% | 1,437,705 | $97M |
| 3 | MORGAN STANLEY | 8.4% | 1,227,701 | $83M |
| 4 | Sanofi | 7.9% | 1,157,926 | $78M |
| 5 | HighTower Advisors, LLC | 5.9% | 870,200 | $59M |
| 6 | STATE STREET CORP | 3.8% | 550,845 | $37M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 486,422 | $33M |
| 8 | BlackRock, Inc. | 2.9% | 425,013 | $29M |
| 9 | Sofinnova Investments, Inc. | 2.8% | 406,029 | $27M |
| 10 | Capital Research Global Investors | 2.7% | 392,847 | $26M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Inhibrx Biosciences Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.8B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$724M
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.2B
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Reference
Frequently asked questions
- When is the Inhibrx Biosciences Inc 2026 annual meeting?
- Inhibrx Biosciences Inc (INBX) holds its 2026 annual shareholder meeting on Wednesday, June 3, 2026.
- What is the record date for the Inhibrx Biosciences Inc 2026 meeting?
- The record date for the Inhibrx Biosciences Inc 2026 meeting is Tuesday, April 7, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Inhibrx Biosciences Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Inhibrx Biosciences Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Inhibrx Biosciences Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Inhibrx Biosciences Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.